Searched for
EMPAGLIFLOZIN GENERIC INDIA
Fresh tailwinds emerge as government comes in again with intent: 7 pharma stocks with upside potential of up to 36%Budget 2026 underlines the government’s intent – in terms of the sectors it will focus on. Now, it is not all of a sudden that the governme...- Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 monthsThe drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Generic versions of key diabetic drug in market double in a monthPost patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and player...
- New affordable diabetes drug Empagliflozin launched in IndiaSeveral domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices follo...
- Indian pharma cos to launch cheaper diabetes medicine at 90% lower price soonDomestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the expiry of Boehrin...
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...
- Nifty healthcare index stocks; Staying bullish on select pharma and hospitalsWhile they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different...
- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...
- Should you stick to largecaps amid volatile Nifty? These 4 stocks have up to 30% upside scopeAs volatility increases, the focus in the market is shifting to stocks which are considered as relatively defensive. These stocks tend to f...
- Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drugBI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making,...
- Himachal Pradesh high court restrains DRL from selling BI's diabetic drug JardianceThe drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jard...
- Boehringer Ingelheim gets interim injunction against Dr. Reddy’s Labs, MSN Labs against copies of anti-diabetes drugIn a statement to ET, BI confirmed it has obtained separate orders granting ad-interim injunction that restrains the two domestic pharmaceu...
- MSN Labs launches patented diabetes pill Jardiance after DRL, heats up potential legal battleEarlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025.
- Dr Reddy's Labs launches copy of BI drug; move may lead to legal battleUnder its brand Vicra, Dr. Reddy's is expected to sell the drug in India at less than a third of the price charged by Boehringer Ingelheim....
- Stocks in the news: RIL, YES Bank, Adani Ports,Cadila Healthcare, HUL and TechMHere are a few stocks that are likely to see some action in Monday’s trade.
- Cadila on the Moon on HCQ lift, awaits Covid-19 vaccine boosterThe drugmaker is one of the two largest manufacturers of hydroxychloroquine (HCQ).
- Market Movers: L&T, Lupin, DRL gain; HDFC twins key drag; 50 stocks enter ‘buy’ zoneHDFC twins and Reliance Industries were among the biggest drags, but a jump in L&T after three ‘large’ order wins cushion the fall to some ...
- Stocks in the news: DMart, HDFC, Dish TV, JSPL, Tata Consumer and GAILJSPL has bagged an order of 2,308 tonne head hardened rails from Kolkata Metro Rail Corporation.
- Boehringer Igelheim aims for top slot with anti-diabetes drug launchWith Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.
Load More
